Protein Selectivity Studies Using GRID-MIFs

Molecular Interaction Fields: Applications in Drug Discovery and ADME Prediction

Volumn 27, Issue , 2006, Pages 43-82

  Fox, Thomas ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Applications; Chemometric analysis; GRID calculations; GRID MIFs; Molecular interaction fields; Pharmacodynamics; Protein selectivity studies

Indexed keywords

APPLICATIONS; PHARMACODYNAMICS;

CHEMOMETRIC ANALYSIS; GRID-MIFS; MOLECULAR INTERACTION FIELDS;

PROTEINS;

EID: 85018231141     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/3527607676.ch3     Document Type: Chapter

References (67)

1. C. J. Manly, S. Louise-May, J. D. Hammer, The impact of informatics and computational chemistry on synthesis and screening, Drug Discovery Today 2001, 6, 1101-1110.
2. Modern Methods of Drug Discovery, A. Hillisch, R. Hilgenfeld (Eds.) Springer Verlag, Berlin, 2003.
3. W. L. Jorgensen, The Many Roles of Computation in Drug Discovery, Science 2004, 303, 1813-1818.
4. H. Matter, W. Schwab, Affinity and selectivity of matrix metalloproteinase inhibitors: A chemometrical study from the perspective of ligands and proteins, J. Med. Chem. 1999, 42, 4506-4523.
5. G. Cruciani, P. J. Goodford, A search for specificity in DNA-drug interactions, J. Mol. Graphics 1994, 12, 116-129.
6. M. Pastor, G. Cruciani, A novel strategy for improving ligand selectivity in receptor-based drug design, J. Med. Chem. 1995, 38, 4637-4647.
7. E. Filipponi, V. Cecchetti, O. Tabarrini, D. Bonelli, A. Fravolini, Chemometric rationalization of the structural and physicochemical basis for selective cyclooxygenase-2 inhibition: Toward more specific ligands, J. Comput.-Aided Mol. Des. 2000, 14, 277-291.
8. M. A. Kastenholz, M. Pastor, G. Cruciani, E. E. J. Haaksma, T. Fox, GRID/ CPCA: A new computational tool to design selective ligands, J. Med. Chem. 2000, 43, 3033-3044.
9. M. Ridderström, I. Zamora, O. Fjellström, T. B. Andersson, Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18, and 2C19 homology models using GRID/CPCA, J. Med. Chem. 2001, 44, 4072-4081.
10. T. Naumann, H. Matter, Structural classification of protein kinases using 3D molecular interaction field analysis of their ligand binding sites: Target family landscapes, J. Med. Chem. 2002, 45, 2366-2378.
11. G. E. Terp, G. Cruciani, I. T. Christensen, F. S. Jørgensen, Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach, J. Med. Chem. 2002, 45, 2675-2684.
12. P. Braiuca, C. Ebert, L. Fischer, L. Gardossi, P. Linda, A homology model of penicillin acylase from Alcaligenes faecalis and in silico evaluation of its selectivity, ChemBioChem 2003, 4, 615-622.
13. H. Ji, R. B. Silverman, H. Li, M. Flinspach, T. L. Poulos, Computer Modeling of Selective Regions in the Active Site of Nitric Oxide Synthases: Implication for the Design of Isoform-Selective Inhibitors, J. Med. Chem. 2003, 46, 5700-5711.
14. M. Kurz, V. Brachvogel, H. Matter, S. Stengelin, H. Thüring, W. Kramer, Insights into the bile acid transportation system: The human ileal lipid-binding protein-cholyltaurine complex and its comparison with homologous structures, Proteins: Struct., Funct. Genet. 2003, 50, 312-328.
15. E. Myshkin, B. Wang, Chemometrical classification of ephrin ligands and Eph kinases using GRID/CPCA approach, J. Chem. Inf. Comput. Sci. 2003, 43, 1004-1010.
16. L. Afzelius, F. Raubacher, A. Karlen, F. S. Jørgensen, T. B. Andersson, C. M. Masimirembwa, I. Zamora, Structural analysis of CYP2C9 and CYP2C5 and an evaluation of commonly used molecular modeling techniques, Drug Metab. Dispos. 2004, 32, 1218-1229.
17. P. Braiuca, G. Cruciani, C. Ebert, L. Gardossi, P. Linda, An innovative application of the "flexible" GRID/PCA computational method: Study of differences in selectivity between PGAs from Escherichia coli and a Providentia rettgeri mutant, Biotechnol. Prog. 2004, 20, 1025-1031.
18. B. Pirard, Peroxisome proliferator-activated receptors target family landscape: A chemometrical approach to ligand selectivity based on protein binding site analysis, J. Comput.-Aided Mol. Des. 2003, 17, 785-796.
19. GRID, Molecular Discovery Ltd., 215 Marsh Road, 1st Floor, HA5 5NE, Pinner, Middlesex, UK, www.moldiscovery.com
20. D. N. A. Boobbyer, P. J. Goodford, P. M. McWhinnie, R. C. Wade, New hydrogen-bond potentials for use in determining energetically favorable binding sites on molecules of known structure, J. Med. Chem. 1989, 32, 1083-1094.
21. P. J. Goodford, A computational procedure for determining energetically favorable binding sites on biologically important macromolecules, J. Med. Chem. 1985, 28, 849-857.
22. R. C. Wade, K. J. Clark, P. J. Goodford, Further development of hydrogen bond functions for use in determining energetically favorable binding sites on molecules of known structure. 1. Ligand probe groups with the ability to form two hydrogen bonds, J. Med. Chem. 1993, 36, 140-147.
23. R. C. Wade, P. J. Goodford, Further development of hydrogen bond functions for use in determining energetically favorable binding sites on molecules of known structure. 2. Ligand probe groups with the ability to form more than two hydrogen bonds, J. Med. Chem. 1993, 36, 148-156.
24. P. Goodford, Multivariate Characterization of Molecules for QSAR Analysis, J. Chemom. 1996, 10, 110-117.
25. GOLPE4.5, Multivariate Infometric Analysis S.r.l., Viale dei Castagni, 16, I-06143 Perugia, Italy.
26. M. Baroni, G. Constantino, G. Cruciani, D. Riganelli, R. Valigi, S. Clementi, Generating Optimal Linear PLS Estimations (GOLPE): An Advanced Chemometric Tool for Handling 3D-QSAR Problems, Quant. Struct.-Act. Relat. 1993, 12, 9-20.
27. M. D. Miller, S. K. Kearsley, D. J. Underwood, R. P. Sheridan, FLOG: a system to select 'quasi-flexible' ligands complementary to a receptor of known threedimensional structure, J. Comput.-Aided Mol. Des. 1994, 8, 153-174.
28. R. P. Sheridan, M. K. Holloway, G. McGaughey, R. T. Mosley, S. B. Singh, A simple method for visualizing the differences between related receptor sites, J. Mol. Graphics Model. 2002, 21, 217-225.
29. S. Wold, K. Esbensen, P. Geladi, Principal component analysis, Chemom. Intell. Lab. Syst. 1987, 2, 37-52.
30. L. Eriksson, E. Johansson, N. Kettaneh-Wold, S.Wold, Multi- and Megavariate Data Analysis, 2001. Umetrics AB.
31. T. Fox, presentation at the International Workshop 'New Approaches in Drug Design & Discovery', Schloss Rauischolzhausen, March 19-22, 2001.
32. J. A. Westerhuis, T Kourti, J. F. Macgregor, Analysis of multiblock and hierarchical PCA and PLS models, J. Chemom. 1998, 12, 301-321.
33. S. Wold, N. Kettaneh, K. Tjessem, Hierarchical multiblock PLS and PC models for easier model interpretation and as an alternative to variable selection, J. Chemom. 1996, 10, 463-482.
34. A. K. Smilde, J. A. Westerhuis, S. de Jong, A framework for sequential multiblock component methods, J. Chemom. 2003, 17, 323-337.
35. T. D. Warner, J. A. Mitchell, Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic, FASEB J. 2004, 18, 790-804.
36. D. Banner, J. Ackermann, A. Gast, K. Gubernator, P. Hadvary, K. Hilpert, L. Labler, E. Myshkin, G. Schmid, T. B. Tschopp, H. Van de, Waterbeemd, B. Wirz, Serine Proteases: 3D Structures, Mechanisms of Action, in Perspectives in Medicinal Chemistry, B. Testa (Ed.), VCH, Weinheim, pp. 27-43, 1993.
37. M. T. Stubbs, W. Bode, A player of many parts: The spotlight falls on thrombin's structure, Thrombosis Res. 1993, 69, 1-58.
38. T Steinmetzer, J. Stürzebecher, Progress in the development of synthetic thrombin inhibitors as new orally active anticoagulants, Curr. Med. Chem. 2004, 11, 2297-2321.
39. F. Al Obeidi, J. A. Ostrem, Factor Xa inhibitors by classical and combinatorial chemistry, Drug Discovery Today 1998, 3, 223-231.
40. S. Ekins, M. J. De Groot, J. P. Jones, Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites, DrugMetab. Dispos. 2001, 29, 936-944.
41. L. Afzelius, C. M. Masimirembwa, A. Karlén, T. B. Anderson, I. Zamora, Discriminant and quantitative PLS analysis of competitive CYP2C9 inhibitors versus non-inhibitors using alignment independent GRIND descriptors, J. Comput.-AidedMol. Des. 2002, 16, 443-458.
42. S. Ekins, J. Berbaum, R. K. Harrison, Generation and validation of rapid computational filters for CYP2D6 and CYP3A4, DrugMetab. Dispos. 2003, 31, 1077-1080.
43. D. Korolev, E. Kirillov, T. Nikolskaya, K. V. Balakin, Y. Nikolsky, Y. A. Ivanenkov, N. P. Savchuk, A. A. Ivashchenko, Modeling of human cytochrome P450-mediated drug metabolism using unsupervised machine learning approach, J. Med. Chem. 2003, 43, 3631-3643.
44. R. G. Susnow, S. L. Dixon, Use of robust classification techniques for the prediction of human cytochrome P450 2D6 inhibition, J. Chem. Inf. Comput. Sci. 2003, 43, 1308-1315.
45. C. W. Locuson II, J. P. Jones, D. A. Rock, Quantitative binding models for CYP2C9 based on benzbromarone analogues, Biochemistry 2004, 43, 6948-6958.
46. Y.-T. Chang, N. S. Gray, G. R. Rosania, D. P. Sutherlin, S. Kwon, T. C. Norman, R. Sarohia, M. Leost, L. Meijer, P. G. Schultz, Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors, Chem. Biol. 1999, 6, 361-375.
47. H. D. Foda, S. Zucker, Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis, Drug Discovery Today 2001, 6, 478-482.
48. J. W. Skiles, N. C. Gonnella, A. Y. Jeng, The Design, Structure, and Therapeutic Application of Matrix Metalloprotease Inhibitors, Curr. Med. Chem. 2001, 8, 425-474.
49. B. C. Finzel, E. T. Baldwin, J. Bryant, G. F. Hess, J. W. Wilks, C. M. Trepod, J. E. Mott, V. P. Marshall, G. L. Petzold, R. A. Poorman, T. J. O'Sullivan, H. J. Schostarez, M. A. Mitchell, Structural characterizations of nonpeptidic thiadiazole inhibitors of matrix metallo proteinases reveal the basis for stromelysin selectivity, Protein Sci. 1998, 7, 2118-2126.
50. J. Schröder, A. Henke, H. Wenzel, H. Brandstetter, H. G. Stammler, A. Stammler, W. D. Pfeiffer, H. Tschesche, Structure-based design and synthesis of potent matrix metallo proteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold, J. Med. Chem. 2001, 44, 3231-3243.
51. V. Lukacova, Y. Zhang, M. Mackov, P. Baricic, S. Raha, J. A. Calvo, S. Balaz, Similarity of Binding Sites of Human Matrix Metalloproteinases, J. Biol. Chem. 2004, 279, 14194-14200.
52. T. S. Rush III, R. Powers, The application of X-ray, NMR, and molecular modeling in the design of MMP inhibitors, Curr. Top. Med. Chem. 2004, 4, 1311-1327.
53. H. M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig, P. E. Bourne, H. M. Berman, I. N. Shindyalov, The Protein Data Bank, Nucleic Acids Res. 2000, 28, 235-242.
54. D. P. Becker, G. DeCrescenzo, J. Freskos, D. P. Getman, S. L. Hockerman, M. Li, P. Mehta, G. E. Munie, C. Swearingen, a-alkyl-a-amino-b-sulphone hydroxamates as potent MMP inhibitors that spare MMP-1, Bioorg. Med. Chem. Lett. 2001, 11, 2723-2725.
55. N. Kucharczyk, A. Loynel, M. Bertrand, G. Tucker, N. Guilbaud, M. Burbridge, P. Pastoureau, A. Fradin, M. Sabatini, J.-L. Fauchere, P. Casara, Solid-phase synthesis of a-substituted 3-bisarylthio N-hydroxy propionamides as specific MMP Inhibitors, Bioorg. Med. Chem. 2002, 10, 531-544.
56. G. E. Terp, I. T. Christensen, F. S. Jørgensen, Structural differences of matrix metalloproteinases. Homology modeling and energy minimization of enzyme-substrate complexes, J. Biomol. Struct. Dynam. 2000, 17, 933-946.
57. B. Lovejoy, A. R. Welch, S. Carr, C. Luong, C. Broka, R. T. Hendricks, J. A. Campbell, K. A. M. Walker, R. Martin, H. Van Wart, M. F. Browner, Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors, Nature Struct. Biol. 1999, 6, 217-221.
58. W. K. Alderton, C. E. Cooper, R. G. Knowles, Nitric oxide synthases: Structure, function and inhibition, Biochem. J. 2001, 357, 593-615.
59. H. Matter, P. Kotsonis, Biology and chemistry of the inhibition of nitric oxide synthases by pteridine-derivatives as therapeutic agents, Med. Res. Rev. 2004, 24, 662-684.
60. K. Kullander, R. Klein, Mechanisms and functions of Eph and ephrin signalling, Nature Rev. Mol. Cell Biol. 2002, 3, 475-486.
61. S. Schmitt, D. Kuhn, G. Klebe, A new method to detect related function among proteins independent of sequence and fold homology, J. Mol. Biol. 2002, 323, 387-406.
62. Z. Deng, C. Chuaqui, J. Singh, Structural Interaction Fingerprint (SIFt): A Novel Method for Analyzing ThreeDimensional Protein-Ligand Binding Interactions, J. Med. Chem. 2004, 47, 337-344.
63. H. A. Carlson, Protein flexibility and drug design: How to hit a moving target, Curr. Opin. Chem. Biol. 2002, 6, 447-452.
64. B. Pirard, Computational methods for the identification and optimisation of high quality leads, Combinatorial Chem. High Throughput Screening 2004, 7, 271-280.
65. K. Kamata, H. Kawamoto, T. Honma, T. Iwama, S.-H. Kim, Structural basis for chemical inhibition of human blood coagulation factor Xa, Proc. Natl. Acad. Sci. U. S. A. 1998, 6630-6635.
66. V. Dhanaraj, Q. Z. Ye, L. L. Johnson, D. J. Hupe, D. F. Ortwine, J. Dunbar, J. R. Rubin, A. Pavlovsky, C. Humblet, T. L. Blundell, X-ray structure of a hydroxamate inhibitor complex of stro melysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily, Structure (London) 1996, 4, 375-386.
67. C. K. Esser, R. L. Bugianesi, C. G. Caldwell, K. T. Chapman, P. L. Durette, N. N. Girotra, I. E. Kopka, T. J. Lanza, D. A. Levorse, M. MacCoss, K. A. Owens, M. M. Ponpipom, J. P. Simeone, R. K. Harrison, L. Niedzwiecki, J. W. Becker, A. I. Marcy, M. G. Axel, A. J. Christen, J. McDonnell, V. L. Moore, J. M. Olszewski, C. Saphos, D. M. Visco, F. Shen, A. Colletti, P. A. Krieter, W. K. Hagmann, Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides, J. Med. Chem. 1997, 40, 1026-1040.